Biopharmaceutical and Medical Research

For the National Cancer Institute (NCI), we operate NCI-Frederick, one of the world's premier cancer and AIDS research facilities. There we support a wide range of research areas, including development of nanotechnology applications for the diagnosis, prevention, and treatment of cancer.

We work with NCI researchers to develop nanoscale devices (less than 100 nanometers in size) that can deliver cancer therapeutic agents and anticancer vaccines at the cellular level. Smaller than a living cell, these tiny drug delivery devices will likely be able to target only malignant cells, sparing healthy cells and reducing the side effects of today's cancer treatments.

To help expedite development of a next-generation anthrax vaccine, we are working with the National Institute of Allergy and Infectious Diseases, NCI, and the U.S. Army to produce and test a promising recombinant protective antigen vaccine. We also help develop vaccines to combat other devastating diseases such as malaria and HIV.

To accelerate translational cancer research, the NCI's new cancer Biomedical Informatics Grid (caBIG) is helping with cross-disciplinary sharing of research between more than 600 cancer researchers from over 50 different cancer centers. SAIC is developing important grid-based middleware, applications, and security for this groundbreaking initiative.